The potential clinical implications of targeted therapies for DLBCL and why the situation is complex
Targeted molecular signatures of DLBCL and upcoming CheckMate 647 trial for PCNSL and PTL
Panel discussion on large cell lymphomas: subtypes, patient selection and mutations
Andrew Zelenetz et al.
What makes TGR-1202 different from other PI3K inhibitors?
Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor